The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
NCT ID: NCT00990197
Last Updated: 2009-10-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Clinical Phase
NA
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-06-30
Study Completion Date
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Continuing to smoke after having a heart attack greatly increases the risk of death and cardiac illness. The nicotine patch is a commonly used pharmacotherapy for smoking cessation and has great potential to help heart attack patients quit smoking. However, due to safety concerns, physicians are often hesitant to prescribe the nicotine patch to patients who have just suffered a heart attack. The STADIA pilot study will assess the feasibility of a large-scale clinical trial investigating safety and efficacy outcomes associated with the nicotine patch immediately following a heart attack. Eligible subjects will be randomized within 48 hours of suffering a heart attack to wear a transdermal nicotine patch on either day 1 or day 2 of the study period. The nicotine patch will deliver nicotine to the patient over the period of 24 hours. Patients will be advised to discuss smoking cessation strategies with their treating physician and subsequent care will be left to the discretion of this physician. The duration of ischemia (loss of blood flow in the heart), patient adherence, incidence of arrhythmia (disorder of the heart rate or rhythm), heart rate, and blood pressure within the two groups will be used to evaluate the safety of transdermal nicotine use immediately after a heart attack.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease
NCT00959972
Coronary Heart Disease
COMPLETED
PHASE4
Smoking Cessation After Acute Coronary Syndrome
NCT03209622
Smoking
Acute Coronary Syndrome
Recurrence
COMPLETED
NA
Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement
NCT02439944
Tobacco Use Disorder
Nicotine Dependence
TERMINATED
PHASE2/PHASE3
Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
NCT00689611
Acute Coronary Syndrome
Myocardial Infarction
Smoking
COMPLETED
PHASE3
Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation
NCT00364156
TOBACCO USE CESSATION
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective
The STADIA Pilot Study will be used to evaluate the feasibility of conducting a three-year multi-centre trial investigating the long-term safety and efficacy outcomes associated with transdermal nicotine use immediately following an acute coronary syndrome (ACS).
Rationale
Patients who initially survive an ACS are at high risk of recurrent cardiac events or cardiovascular death. Within the first 6 months alone, 12% of patients will die or suffer another ACS, while another 23% will require revascularization for angina. Patients who are able to quit smoking reduce their chances of suffering a recurrent ACS or cardiovascular death within the next year by ≥ 50%. After surviving an ACS, most patients are highly motivated to stop smoking. However, as nicotine is an extremely addictive psychoactive drug, up to 60% of patients who attempt to quit relapse. Hospitalization following an ACS provides an opportunity for smokers to quit, as smoking while in hospital is prohibited. However, abstinence while hospitalized also precipitates intense nicotine withdrawal symptoms, which are largely responsible for the high rates of smoking relapse. Nicotine replacement therapy (NRT) can ameliorate many of these symptoms and increase the chances that smokers continue to abstain from tobacco use after discharge. Of the available NRTs, transdermal nicotine is associated with the least severe cardiovascular effects, as it delivers nicotine more gradually (with lower peak values) than nicotine gum or inhalers. Although transdermal nicotine more than doubles long-term smoking cessation rates when compared with placebo, it is rarely prescribed by physicians in the weeks immediately following an ACS because the possible cardiovascular effects of nicotine after an ACS have yet to be systematically evaluated.
Methods
A total of 30 patients will be randomized within 48-hours of suffering an ACS from the Jewish General Hospital (Montreal, QC) and collaborating centres. Prior to randomization, all patients will receive standardized smoking cessation counselling. Subjects who satisfy the inclusion and exclusion criteria for the trial will be randomized within 48 hours of suffering an ACS to wear a transdermal nicotine patch on either day 1 or day 2 of the study period. Subjects will apply a patch the morning of their treatment day and keep it on for 24 hours. Patients will be advised to discuss smoking cessation strategies with their treating physician and subsequent care will be left to the discretion of this physician. Twenty-four hour Holter monitoring will be used to measure heart rate, incidence of arrhythmia, and the duration of ischemic events at day 1 and day 2 of the study period. Systolic and diastolic blood pressure will be assessed via 24-hour Ambulatory blood pressure monitoring (ABPM). ABPM will be used on day 1 and day 2 of the study period. On day 1 the study nurse will record the severity of nicotine withdrawal symptoms, side effects, any smoking relapses and if so, how many cigarettes were smoked, and any medications they are currently taking. On day 7 and 14 patients will be contacted by telephone to determine the severity of nicotine withdrawal symptoms, any smoking relapses and if so, how many cigarettes were smoked and any medications they are currently taking. Cardiovascular events will be assessed by patient monitoring and by a study nurse. Nicotine withdrawal symptoms according to the Hughes-Hatsukami symptom scale and common nicotine patch side effects, severity-rated on a five-point scale, will be determined through study nurse inquiries on days 1, 7, and 14 (6). Carbon monoxide monitors will be used to measure levels of expired CO at baseline. Participants whose levels of expired CO exceed 10 ppm will be classified as smokers.
Significance
If shown to be safe and effective, transdermal nicotine will have a major impact on the secondary prevention of recurrent cardiac events on the 20,000 Canadian smokers who suffer an ACS each year.
The STADIA Pilot Study will be used to evaluate the feasibility of conducting a three-year multi-centre trial investigating the long-term safety and efficacy outcomes associated with transdermal nicotine use immediately following an acute coronary syndrome (ACS).
Rationale
Patients who initially survive an ACS are at high risk of recurrent cardiac events or cardiovascular death. Within the first 6 months alone, 12% of patients will die or suffer another ACS, while another 23% will require revascularization for angina. Patients who are able to quit smoking reduce their chances of suffering a recurrent ACS or cardiovascular death within the next year by ≥ 50%. After surviving an ACS, most patients are highly motivated to stop smoking. However, as nicotine is an extremely addictive psychoactive drug, up to 60% of patients who attempt to quit relapse. Hospitalization following an ACS provides an opportunity for smokers to quit, as smoking while in hospital is prohibited. However, abstinence while hospitalized also precipitates intense nicotine withdrawal symptoms, which are largely responsible for the high rates of smoking relapse. Nicotine replacement therapy (NRT) can ameliorate many of these symptoms and increase the chances that smokers continue to abstain from tobacco use after discharge. Of the available NRTs, transdermal nicotine is associated with the least severe cardiovascular effects, as it delivers nicotine more gradually (with lower peak values) than nicotine gum or inhalers. Although transdermal nicotine more than doubles long-term smoking cessation rates when compared with placebo, it is rarely prescribed by physicians in the weeks immediately following an ACS because the possible cardiovascular effects of nicotine after an ACS have yet to be systematically evaluated.
Methods
A total of 30 patients will be randomized within 48-hours of suffering an ACS from the Jewish General Hospital (Montreal, QC) and collaborating centres. Prior to randomization, all patients will receive standardized smoking cessation counselling. Subjects who satisfy the inclusion and exclusion criteria for the trial will be randomized within 48 hours of suffering an ACS to wear a transdermal nicotine patch on either day 1 or day 2 of the study period. Subjects will apply a patch the morning of their treatment day and keep it on for 24 hours. Patients will be advised to discuss smoking cessation strategies with their treating physician and subsequent care will be left to the discretion of this physician. Twenty-four hour Holter monitoring will be used to measure heart rate, incidence of arrhythmia, and the duration of ischemic events at day 1 and day 2 of the study period. Systolic and diastolic blood pressure will be assessed via 24-hour Ambulatory blood pressure monitoring (ABPM). ABPM will be used on day 1 and day 2 of the study period. On day 1 the study nurse will record the severity of nicotine withdrawal symptoms, side effects, any smoking relapses and if so, how many cigarettes were smoked, and any medications they are currently taking. On day 7 and 14 patients will be contacted by telephone to determine the severity of nicotine withdrawal symptoms, any smoking relapses and if so, how many cigarettes were smoked and any medications they are currently taking. Cardiovascular events will be assessed by patient monitoring and by a study nurse. Nicotine withdrawal symptoms according to the Hughes-Hatsukami symptom scale and common nicotine patch side effects, severity-rated on a five-point scale, will be determined through study nurse inquiries on days 1, 7, and 14 (6). Carbon monoxide monitors will be used to measure levels of expired CO at baseline. Participants whose levels of expired CO exceed 10 ppm will be classified as smokers.
Significance
If shown to be safe and effective, transdermal nicotine will have a major impact on the secondary prevention of recurrent cardiac events on the 20,000 Canadian smokers who suffer an ACS each year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Smoking Cessation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Day 1
Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
Group Type
ACTIVE_COMPARATOR
Transdermal nicotine patch
Intervention Type
DRUG
Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
Day 2
Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
Group Type
ACTIVE_COMPARATOR
Transdermal nicotine patch
Intervention Type
DRUG
Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transdermal nicotine patch
Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Nicoderm CQ, Biovail Pharmaceuticals
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Current smoker, ≥ 10 cigarettes per day, on average, for the past year
* Suffered an enzyme-positive ACS (Troponin T, Troponin I, or CK-MD) and planned hospitalization of ≥ 48 hours
* Motivated to quit smoking
* Current smoker, ≥ 10 cigarettes per day, on average, for the past year
* Suffered an enzyme-positive ACS (Troponin T, Troponin I, or CK-MD) and planned hospitalization of ≥ 48 hours
* Motivated to quit smoking
Exclusion Criteria
* Current use of any medical therapy for smoking cessation
* History of alcohol or controlled substance abuse
* History of severe dermatitis
* Current diagnosis of unstable psychiatric illness requiring medication
* Suffered an ACS as a complication of a hospitalization for a different condition (i.e. postoperatively)
* Pregnancy or lactation
* Likely to be unavailable for follow-up
* Unable to read and understand English or French
* History of alcohol or controlled substance abuse
* History of severe dermatitis
* Current diagnosis of unstable psychiatric illness requiring medication
* Suffered an ACS as a complication of a hospitalization for a different condition (i.e. postoperatively)
* Pregnancy or lactation
* Likely to be unavailable for follow-up
* Unable to read and understand English or French
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Tobacco Control Research Initiative
OTHER
Sponsor Role
collaborator
Sir Mortimer B. Davis - Jewish General Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jewish General Hospital/McGill University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark J Eisenberg, MD MPH
Role: PRINCIPAL_INVESTIGATOR
Jewish General Hospital/McGill University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SMDB Jewish General Hospital
Montreal, Quebec, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Sauer WH, Berlin JA, Strom BL, Miles C, Carson JL, Kimmel SE. Cigarette yield and the risk of myocardial infarction in smokers. Arch Intern Med. 2002 Feb 11;162(3):300-6. doi: 10.1001/archinte.162.3.300.
Reference Type
BACKGROUND
Cardiovascular Disease Surveillance. Laboratory Centre for Disease Control, Statistics Canada 2002, Candian Institutes for Health Information (CIHI), 2002.
Reference Type
BACKGROUND
Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch Intern Med. 1994 May 9;154(9):989-95.
Reference Type
BACKGROUND
Frid D, Ockene IS, Ockene JK, Merriam P, Goldberg R, Kristeller J, Barrett S. Severity of angiographically proven coronary artery disease predicts smoking cessation. Am J Prev Med. 1991 May-Jun;7(3):131-5.
Reference Type
BACKGROUND
Brummett BH, Babyak MA, Mark DC, Williams RB, Siegler IC, Clapp-Channing N, Barefoot JC. Predictors of smoking cessation in patients with a diagnosis of coronary artery disease. J Cardiopulm Rehabil. 2002 May-Jun;22(3):143-7. doi: 10.1097/00008483-200205000-00003.
Reference Type
BACKGROUND
Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol. 1992 Oct;60(5):689-97. doi: 10.1037//0022-006x.60.5.689.
Reference Type
BACKGROUND
Stapleton J. Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res. 1998 Jun;7(2):187-203. doi: 10.1177/096228029800700206.
Reference Type
BACKGROUND
Rigotti NA, Arnsten JH, McKool KM, Wood-Reid KM, Pasternak RC, Singer DE. Smoking by patients in a smoke-free hospital: prevalence, predictors, and implications. Prev Med. 2000 Aug;31(2 Pt 1):159-66. doi: 10.1006/pmed.2000.0695.
Reference Type
BACKGROUND
Jorenby DE, Hatsukami DK, Smith SS, Fiore MC, Allen S, Jensen J, Baker TB. Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology (Berl). 1996 Nov;128(2):130-8. doi: 10.1007/s002130050118.
Reference Type
BACKGROUND
Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993 Oct;22(4):1159-67. doi: 10.1016/0735-1097(93)90431-y.
Reference Type
BACKGROUND
Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther. 1990 Mar;47(3):331-7. doi: 10.1038/clpt.1990.36.
Reference Type
BACKGROUND
Gourlay S. The pros and cons of transdermal nicotine therapy. Med J Aust. 1994 Feb 7;160(3):152-9.
Reference Type
BACKGROUND
Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med. 1988 Nov 17;319(20):1318-30. doi: 10.1056/NEJM198811173192005. No abstract available.
Reference Type
BACKGROUND
Kaijser L, Berglund B. Effect of nicotine on coronary blood-flow in man. Clin Physiol. 1985 Dec;5(6):541-52. doi: 10.1111/j.1475-097x.1985.tb00767.x.
Reference Type
BACKGROUND
Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. JAMA. 1991 Dec 11;266(22):3133-8.
Reference Type
BACKGROUND
Pickering TG, Schwartz JE, James GD. Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Clin Exp Pharmacol Physiol. 1995 Mar;22(3):226-31. doi: 10.1111/j.1440-1681.1995.tb01986.x.
Reference Type
BACKGROUND
Palatini P, Pessina AC, Graniero GR, Canali C, Mormino P, Dorigatti F, Accurso V, Michieletto M, Ferrarese E, Vriz O, et al. [The relationship between overweight, life style and casual and 24-hour pressures in a population of male subjects with mild hypertension. The results of the HARVEST study]. G Ital Cardiol. 1995 Aug;25(8):977-89. Italian.
Reference Type
BACKGROUND
Zevin S, Jacob P 3rd, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther. 1998 Jul;64(1):87-95. doi: 10.1016/S0009-9236(98)90026-1.
Reference Type
BACKGROUND
Mahmarian JJ, Moye LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, Verani MS, Byrd WG, Pratt CM. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. 1997 Jul;30(1):125-30. doi: 10.1016/s0735-1097(97)00128-9.
Reference Type
BACKGROUND
Longo LD. The biological effects of carbon monoxide on the pregnant woman, fetus, and newborn infant. Am J Obstet Gynecol. 1977 Sep 1;129(1):69-103. doi: 10.1016/0002-9378(77)90824-9. No abstract available.
Reference Type
BACKGROUND
Rietbrock N, Kunkel S, Worner W, Eyer P. Oxygen-dissociation kinetics in the blood of smokers and non-smokers: interaction between oxygen and carbon monoxide at the hemoglobin molecule. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jan;345(1):123-8. doi: 10.1007/BF00175479.
Reference Type
BACKGROUND
Allred EN, Bleecker ER, Chaitman BR, Dahms TE, Gottlieb SO, Hackney JD, Pagano M, Selvester RH, Walden SM, Warren J. Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med. 1989 Nov 23;321(21):1426-32. doi: 10.1056/NEJM198911233212102.
Reference Type
BACKGROUND
Allen SS, Hatsukami D, Gorsline J. Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group. Prev Med. 1994 Mar;23(2):190-6. doi: 10.1006/pmed.1994.1026.
Reference Type
BACKGROUND
Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995 May 4;332(18):1198-203. doi: 10.1056/NEJM199505043321804.
Reference Type
BACKGROUND
Peters RW, Benowitz NL, Valenti S, Modin G, Fisher ML. Electrophysiologic effects of cigarette smoking in patients with and without chronic beta-blocker therapy. Am J Cardiol. 1987 Nov 1;60(13):1078-82. doi: 10.1016/0002-9149(87)90356-0.
Reference Type
BACKGROUND
Gillum RF, Ingram DD, Makuc DM. White blood cell count and stroke incidence and death. The NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994 May 1;139(9):894-902. doi: 10.1093/oxfordjournals.aje.a117095.
Reference Type
BACKGROUND
Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA. 1985 Oct 11;254(14):1932-7.
Reference Type
BACKGROUND
Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation. 1995 Mar 15;91(6):1872-85. doi: 10.1161/01.cir.91.6.1872.
Reference Type
BACKGROUND
Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113-29. doi: 10.1146/annurev.med.54.101601.152209. Epub 2001 Dec 3.
Reference Type
BACKGROUND
Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999 Jun;36(6):425-38. doi: 10.2165/00003088-199936060-00004.
Reference Type
BACKGROUND
Dacosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, Cerisier A, Verneyre H. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J. 1993 Dec;14(12):1709-11. doi: 10.1093/eurheartj/14.12.1709.
Reference Type
BACKGROUND
Warner JG Jr, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch. Ann Intern Med. 1994 Apr 15;120(8):695. doi: 10.7326/0003-4819-120-8-199404150-00023. No abstract available.
Reference Type
BACKGROUND
Ottervanger JP, Festen JM, de Vries AG, Stricker BH. Acute myocardial infarction while using the nicotine patch. Chest. 1995 Jun;107(6):1765-6. doi: 10.1378/chest.107.6.1765.
Reference Type
BACKGROUND
Hwang SL WM. Heart attacks reported in patch users still smoking. Wall Street Journal 1992;(June 19):B1.
Reference Type
BACKGROUND
Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, Offord KP. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl). 1995 Dec;122(3):215-22. doi: 10.1007/BF02246542.
Reference Type
BACKGROUND
Pierce JR Jr. Stroke following application of a nicotine patch. Ann Pharmacother. 1994 Mar;28(3):402. doi: 10.1177/106002809402800320. No abstract available.
Reference Type
BACKGROUND
Jackson M. Cerebral arterial narrowing with nicotine patch. Lancet. 1993 Jul 24;342(8865):236-7. doi: 10.1016/0140-6736(93)92323-l. No abstract available.
Reference Type
BACKGROUND
Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, Hays JT, Lewis SF, Baker TB. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995 Nov 1;274(17):1347-52.
Reference Type
BACKGROUND
Arnaot MR. Treating heart disease. Nicotine patches may not be safe. BMJ. 1995 Mar 11;310(6980):663-4. doi: 10.1136/bmj.310.6980.663c. No abstract available.
Reference Type
BACKGROUND
Treating tobacco dependence: a report of the Surgeon General. Washington, DC: Department of Health and Human Services, 2000.
Reference Type
BACKGROUND
Freedman D PRPR. Statistics. New York: Norton Publishers, 1978.
Reference Type
BACKGROUND
Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000 Apr 10;160(7):939-44. doi: 10.1001/archinte.160.7.939.
Reference Type
BACKGROUND
Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ. 1994 Jan 1;308(6920):21-6. doi: 10.1136/bmj.308.6920.21.
Reference Type
BACKGROUND
Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994 Jun 22-29;271(24):1940-7.
Reference Type
BACKGROUND
Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994 Jan 15;343(8890):139-42. doi: 10.1016/s0140-6736(94)90933-4.
Reference Type
BACKGROUND
Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care. 2000 Oct;45(10):1200-62.
Reference Type
BACKGROUND
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2001;(3):CD000146. doi: 10.1002/14651858.CD000146.
Reference Type
BACKGROUND
Hughes JR, Glaser M. Transdermal nicotine for smoking cessation. Health Values 1993; 17(2):25-31.
Reference Type
BACKGROUND
American Medical Association. Drug Evaluations Annual 1994. Chicago: American Medical Association 1993.
Reference Type
BACKGROUND
Palmer KJ, Buckley MM, Faulds D. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992 Sep;44(3):498-529. doi: 10.2165/00003495-199244030-00011.
Reference Type
BACKGROUND
Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998 Apr;18(4):297-308. doi: 10.2165/00002018-199818040-00005.
Reference Type
BACKGROUND
Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland M, Antonuccio DO, Hartman N, McGovern PG. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996 Dec 12;335(24):1792-8. doi: 10.1056/NEJM199612123352402.
Reference Type
BACKGROUND
Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther. 1998 Jul;12(3):239-44. doi: 10.1023/a:1007757530765.
Reference Type
BACKGROUND
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
Reference Type
BACKGROUND
Moyer D. Chapter 13: Physical fitness and carbon monoxide. Tobacco Reference Guide 2000;30-34.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
016026
Identifier Type: -
Identifier Source: secondary_id
05-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Nicotine Patch, Blood Flow and Oxidative Stress Study
NCT00954096
COMPLETED
NA
Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation
NCT01622998
COMPLETED
PHASE4
Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II
NCT00734617
COMPLETED
PHASE3
Nicotine Replacement Therapy and Cardiovascular Disease
NCT02195739
UNKNOWN
Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation
NCT00289653
COMPLETED
NA
Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)
NCT01055886
COMPLETED
NA
Cytisine Compared to Combination NRT in Relapsed Smokers
NCT04286295
TERMINATED
NA
Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling
NCT01623505
COMPLETED
PHASE4
Nicotine Treatment of Mild Cognitive Impairment (MCI)
NCT00091468
UNKNOWN
PHASE1
Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1
NCT00158171
COMPLETED
PHASE2
Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence
NCT01208935
COMPLETED
PHASE2/PHASE3
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
NCT01574703
COMPLETED
PHASE4
Combination Nicotine Patch / Lorcaserin for Smoking Cessation
NCT02906644
COMPLETED
PHASE2
Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)
NCT00000444
COMPLETED
PHASE4
Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine
NCT00956943
COMPLETED
PHASE2
Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation
NCT02859142
COMPLETED
PHASE4
Long-term Effectiveness of Mailed Nicotine Replacement Therapy: A 5-year Follow-up
NCT03097445
COMPLETED
NA
Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
NCT01771627
COMPLETED
NA
Improving the Efficacy of Anti-Nicotine Immunotherapy
NCT01280968
COMPLETED
PHASE2
Effect of Nicotine Pouches on The Underlying Normal Electrocardiogram
NCT07057440
COMPLETED
NA
Smoking and Ventricular Repolarization
NCT03916341
COMPLETED
NA
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
NCT00894166
COMPLETED
PHASE3
Non-Nicotine Agents for Smoking Cessation
NCT00108537
COMPLETED
PHASE3
Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3
NCT00390559
COMPLETED
NA
Evaluation of the Electronic Cigarette Withdrawal Syndrome
NCT06066996
RECRUITING
EARLY_PHASE1